HC Wainwright Reiterates Buy Rating for MiNK Therapeutics (NASDAQ:INKT)

Posted by Tyrone Williams on Nov 15th, 2024

MiNK Therapeutics (NASDAQ:INKT – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, Robert W. Baird cut their price target on MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday.

Get Our Latest Report on INKT

MiNK Therapeutics Stock Performance

INKT stock opened at $0.75 on Friday. The stock’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.85. The stock has a market capitalization of $29.66 million, a price-to-earnings ratio of -1.53 and a beta of 0.05. MiNK Therapeutics has a 1 year low of $0.57 and a 1 year high of $1.90.

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, analysts predict that MiNK Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 21.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

About MiNK Therapeutics

(Get Free Report)

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.